Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

By A. Bardia, Ingrid A. Mayer, L. Vahdat, S. Tolaney, S. Isakoff, J. Diamond, J. O’Shaughnessy, R. Moroose, A. Santin, V. Abramson and 9 more. New England Journal of Medicine, 2019

679 citations recorded by the source corpus.

BACKGROUND Standard chemotherapy is associated with low response rates and short progression‐free survival among patients with pretreated metastatic triple‐negative breast cancer. Sacituzumab govitecan‐hziy is an antibody–drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell‐surface antigen 2 (Trop‐2), with SN‐38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan‐hziy enables delivery of high concentrations of SN‐38 to tumors. METHODS We conducted a phase 1/2 single‐group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan‐hziy intravenously on days 1 and 8 of each 21‐day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan‐hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple‐negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression‐free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS The 108 patients with triple‐negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression‐free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS Sacituzumab govitecan‐hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple‐negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU‐132‐01 ClinicalTrials.gov number, NCT01631552.)

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/542c4ada33df15261faaf1f12f001eb9912ae437

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

  1. M. Jorge Cardoso
  2. Larry Norton
  3. Yongheng Chen
  4. S. Leonov
  5. Huajun Zhang
  6. Lin Chen
  7. Na Liu
  8. Yun R Li

In Pulmonary and Respiratory Medicine

  1. Yongheng Chen
  2. S. Leonov
  3. Huajun Zhang
  4. Lin Chen
  5. Na Liu
  6. Yun R Li
  7. Yulia Merkher

Citations in the corpus